Connection

Christoph Correll to Vesicular Monoamine Transport Proteins

Back to Details
This is a "connection" page, showing publications Christoph Correll has written about Vesicular Monoamine Transport Proteins.
Christoph Correll
Connection Strength
2.020
Vesicular Monoamine Transport Proteins
  1. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018; 12:1215-1238.
    View in: PubMed
    Score: 0.758
  2. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder. Psychopharmacol Bull. 2017 08 01; 47(3):53-60.
    View in: PubMed
    Score: 0.718
  3. The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study. J Clin Psychiatry. 2017 Nov/Dec; 78(9):1344-1350.
    View in: PubMed
    Score: 0.183
  4. Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment. J Clin Psychiatry. 2017 Sep/Oct; 78(8):1136-1147.
    View in: PubMed
    Score: 0.181
  5. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder. Psychopharmacol Bull. 2017 08 01; 47(3):69-76.
    View in: PubMed
    Score: 0.180
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.